The apoptotic marker (cleaved caspase 3) and proliferation marker (Ki67 and PCNA) staining ascertained that UBAP2L knockdown enhance the anti-tumor activity of sunitinib in vivo through the inhibition of proliferation and the promotion of apoptosis (Fig. 3H). Here, UBAP2L is linked to neoplasm.